3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
17
Prostatic Neoplasms
12
Lung Neoplasms
10
Squamous Cell Carcinoma of Head and Neck
5
Prostatic Neoplasms, Castration-Resistant
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Endometrial Neoplasms
4
Neoplasms
3
Breast Neoplasms
3
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Salivary Gland Neoplasms
2
Oropharyngeal Neoplasms
2
Non-Muscle Invasive Bladder Neoplasms
2
Neoplasm Metastasis
2
Nasopharyngeal Carcinoma
2
Lymphoid Interstitial Pneumonia
2
Carcinoma, Transitional Cell
2
Carcinoma
2
Anatomic Stage II Breast Cancer AJCC v8
2
Anatomic Stage I Breast Cancer AJCC v8
2
Uterine Neoplasms
1
Urothelial Cancer
1
Triple Negative Breast Neoplasms
1
Tongue Neoplasms
1
Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7
1
Stage I Prostate Adenocarcinoma AJCC v7
1
Solid Tumors
1
Small Cell Lung Carcinoma
1
Selected Subjects With Advanced Solid Tumors
1
Interventions
Paclitaxel
12
Carboplatin
12
Bevacizumab
11
liposomal doxorubicin
8
Specimen Handling
8
olaparib
7
Magnetic Resonance Spectroscopy
7
Topotecan
4
Gemcitabine
4
Biopsy
4
pembrolizumab
3
mirvetuximab soravtansine
3
Taxes
3
Doxorubicin
3
sarilumab
2
niraparib
2
cemiplimab
2
cediranib
2
Immunoglobulin G
2
Disulfides
2
1-dodecylpyridoxal
2
trastuzumab deruxtecan
1
tocilizumab
1
sotorasib
1
peposertib
1
pelcitoclax
1
palbociclib
1
nilotinib
1
neratinib
1
irinotecan sucrosofate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Fallopian Tube Neoplasms
×
Docetaxel
×
30 days
×
Clear all
NCT03740165
2026-05-04
KEYLYNK-001
Merck Sharp & Dohme LLC
Phase 3
Completed
1,367 enrolled
29 charts